Biogen Inc (BIIB)
268.17
+2.44 +0.92%
NASDAQ
Apr 9, 20:00
USD
Biogen Price:
268.17 for April 9, 2021View 4,000+ financial data types
Browse...
View Full Chart
Price Chart
Export Data
Save Image
Print Image
For advanced charting, view our full-featured
Fundamental Chart
Historical Price Data
View and export this data going back to 1991.
Start your Free Trial
Export Data
Date Range:
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| April 9, 2021 | 265.73 | 268.59 | 263.50 | 268.17 | 873329.0 |
| April 8, 2021 | 272.20 | 272.20 | 265.37 | 265.73 | 800861.0 |
| April 7, 2021 | 272.00 | 272.00 | 267.18 | 268.02 | 851417.0 |
| April 6, 2021 | 276.17 | 276.50 | 271.30 | 271.76 | 1.007M |
| April 5, 2021 | 279.24 | 279.92 | 276.63 | 277.88 | 744858.0 |
| April 1, 2021 | 280.00 | 281.88 | 278.00 | 278.71 | 996386.0 |
| March 31, 2021 | 276.32 | 280.83 | 274.39 | 279.75 | 1.136M |
| March 30, 2021 | 273.79 | 279.45 | 273.06 | 276.01 | 882170.0 |
| March 29, 2021 | 275.75 | 278.60 | 273.14 | 276.08 | 794743.0 |
| March 26, 2021 | 272.21 | 277.11 | 271.03 | 276.63 | 665479.0 |
| March 25, 2021 | 267.47 | 280.00 | 264.36 | 273.97 | 1.685M |
| March 24, 2021 | 267.04 | 270.74 | 265.66 | 265.69 | 951795.0 |
| March 23, 2021 | 272.73 | 273.10 | 266.00 | 267.21 | 888091.0 |
| March 22, 2021 | 267.34 | 273.86 | 266.00 | 272.34 | 1.169M |
| March 19, 2021 | 261.43 | 269.35 | 261.12 | 267.07 | 2.118M |
| March 18, 2021 | 262.01 | 267.03 | 261.52 | 262.27 | 885240.0 |
| March 17, 2021 | 258.50 | 267.29 | 257.22 | 264.15 | 1.093M |
| March 16, 2021 | 261.81 | 265.99 | 258.07 | 259.92 | 1.422M |
| March 15, 2021 | 268.02 | 271.43 | 250.42 | 260.13 | 2.830M |
| March 12, 2021 | 266.66 | 267.49 | 261.72 | 266.13 | 1.034M |
| March 11, 2021 | 263.06 | 268.00 | 260.55 | 267.44 | 1.596M |
| March 10, 2021 | 269.52 | 269.52 | 262.60 | 262.61 | 1.736M |
| March 9, 2021 | 272.59 | 278.24 | 266.38 | 266.49 | 1.769M |
| March 8, 2021 | 270.70 | 278.87 | 267.48 | 270.01 | 1.164M |
| March 5, 2021 | 265.83 | 273.33 | 262.44 | 270.71 | 1.062M |
There is no data for the selected date range.
An error occurred. Please try again by refreshing your browser or contact us with details of your problem.
Advertisement
Price Definition
The price of a security measures the cost to purchase 1 share of a security. For a company, price can be multiplied by shares outstanding to find the market capitalization (value of the company).
Price Benchmarks
| Eli Lilly and Co | 184.49 |
| Sage Therapeutics Inc | 76.61 |
| Cassava Sciences Inc | 41.57 |
Price Range, Past 5 Years
| Minimum | 206.88 | Jun 27 2016 |
| Maximum | 383.83 | Jul 25 2018 |
| Average | 283.32 |
Price Related Metrics
| PE Ratio | 10.97 |
| PS Ratio | 3.218 |
| Price to Book Value | 3.818 |
| Price to Free Cash Flow | 11.76 |
| Earnings Yield | 9.12% |
| Market Cap | 40.85B |
| Operating PE Ratio | 9.73 |
| Normalized PE Ratio | 13.81 |
News
Provention Bio downgraded on FDA feedback, Citi sizes up Zuranolone success on Sage, and more in today’s analyst action
SA Breaking News 04/09 09:11 ET
SA Breaking News 04/09 09:11 ET
Analyst Actions: RBC Capital Adjusts Biogen's Price Target to $263 From $257, Keeps Sector Perform Rating
MT Newswires 04/08 08:53 ET
MT Newswires 04/08 08:53 ET
Biogen Wins European Commission Approval for Multiple Sclerosis Treatment
MT Newswires 04/07 08:15 ET
MT Newswires 04/07 08:15 ET
JP Morgan physician survey finds support for Lilly's donanemab in Alzheimer's
SA Breaking News 04/06 10:29 ET
SA Breaking News 04/06 10:29 ET
FDA advisers reiterate case against approval of Biogen/Eisai's aducanumab for Alzheimer's
SA Breaking News 04/01 08:51 ET
SA Breaking News 04/01 08:51 ET
Advertisement
